2025-11-16 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the provided data, formatted as requested.

## TG Therapeutics (TGTX) Analysis

**0. Executive Summary**

TGTX, a biopharmaceutical company, exhibits a mixed outlook. While recent earnings and revenue growth are positive, historical performance compared to the S&P 500 is volatile.  Recent news and technical indicators present a complex picture requiring careful consideration. Analyst sentiment is generally positive, but significant price target variability exists.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TGTX
*   **Company:** TG Therapeutics Inc.
*   **Description:** A biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 78.59%
*   **VOO Cumulative Return:** 98.45%
*   **Absolute Deviation:** -17.9
*   **Relative Deviation:** 20.4 (on a scale where min/max deviation = 0/100)

**Analysis:**

TGTX has underperformed the S&P 500 (VOO) over the analyzed period. The relative deviation of 20.4 suggests that TGTX's performance is currently closer to its historical underperformance range relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2015-2017  | -5.0% | 73.5% | -33.0% | 0.1  | 1.3    |
| 2016-2018  | -12.0% | 73.5% | -27.0% | 0.0  | 0.7    |
| 2017-2019  | 74.0% | 74.1% | 52.0%  | 0.0  | 1.8    |
| 2018-2020  | 316.0% | 74.1% | 293.0% | 0.1  | 8.3    |
| 2019-2021  | 124.0% | 74.1% | 78.0%  | 0.3  | 3.0    |
| 2020-2022  | -71.0% | 77.8% | -71.0% | -0.0 | 1.9    |
| 2021-2023  | -284.0% | 77.8% | -285.0% | -1.0 | 2.7    |
| 2022-2024  | 56.0% | 77.8% | 36.0%  | -1.0 | 4.8    |
| 2023-2025  | 79.0% | 80.6% | 16.0%  | -0.1 | 4.9    |

*   **CAGR:** Highly variable, indicating periods of significant growth and decline.
*   **MDD:** Consistently high Maximum Drawdown values suggest significant risk.
*   **Alpha:**  Ranges widely, showing periods of both outperformance and underperformance relative to the market. The large negative Alpha values in 2021-2023 are concerning.
*   **Beta:** Generally low, and even negative in recent years, suggesting the stock's price is not strongly correlated with the overall market.
*   **Cap(B):** Fluctuation indicates changes in the company's capitalization.

**2. Recent Stock Price Movement**

*   **Current Price:** 31.0
*   **Previous Close:** 30.96
*   **Change:** 0.13
*   **5-day Moving Average:** 30.876
*   **20-day Moving Average:** 33.1997
*   **60-day Moving Average:** 33.2316

**Analysis:**

The current price is slightly above the previous close, indicating a small positive change. However, the price is below both the 20-day and 60-day moving averages, suggesting a potential short-term downtrend or consolidation phase.

**3. Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 34.73 (Approaching oversold territory)
*   **PPO:** -1.06 (Negative, indicating potential downtrend)
*   **Hybrid Signal:** Sell 80% of holdings (Cash Ratio: 80% on 2025-10-16), reflecting a risky situation according to the MRI of 0.5
*   **Recent (20-day) Relative Deviation Change:** 0.7 (+) (Short-term upward trend)
*   **Expected Return (%):** -111.6 (Significantly negative, indicating substantial underperformance vs S&P 500 if investing long term)

**Analysis:**

*   **MRI:** Suggests a medium investment recommendation, but approaching the higher end of the risk spectrum.
*   **RSI:**  Nearing oversold, which *could* signal a potential buying opportunity, but needs confirmation.
*   **PPO:**  Negative PPO reinforces the potential downtrend.
*   **Hybrid Signal:** The "Sell" signal and high cash ratio indicate caution due to perceived risk.
*   **Relative Deviation Change:** The recent positive change in relative deviation is a positive sign.
*   **Expected Return:** A very negative expected return is concerning and suggests a significant underperformance is anticipated compared to the S&P 500 over the long term.
*   **Price Change:** The minor price change (0.13) reflects a relatively small movement, not indicating any drastic immediate volatility.

**4. Recent News & Significant Events**

*   **Negative News:**
    *   "TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results" suggests significant negative impact from competitor data.
    *   "TG Therapeutics (TGTX) Margin Miss Challenges Growth-Driven Profitability Narrative" raises concerns about profitability.
*   **Positive News:**
    *   "Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term" presents a bullish long-term view.
    *   "TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised" indicates positive recent financial performance.
    *   "TG Therapeutics (TGTX) Margin Miss Challenges Growth-Driven Profitability Narrative"
    *    "TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit" provides an opportunity for the company to share it's vision with a wider audience
*   **Neutral News:**
    *   "TG Therapeutics (TGTX): Exploring Valuation as Growth Prospects Spark Investor Interest" explores the company's valuation.

**Analysis:**

The news is mixed. The negative news regarding Roche's results and margin concerns is a significant headwind. The positive earnings and revenue news provide some counterbalance, but the "crumbling" headline is hard to ignore.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.78 (~Buy)
*   **Number of Opinions:** 7
*   **Target Price:**
    *   **Average:** 44.29
    *   **High:** 60.00
    *   **Low:** 13.00
*   **Recent Rating Changes:**  No changes provided

**Analysis:**

Analysts are generally bullish on TGTX, with a consensus "Buy" rating. However, the wide range in target prices (13.00 to 60.00) suggests considerable uncertainty and disagreement about the company's future value.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | 2.69  | 0.16 B$    |
| 2025-08-08 | 0.19  | 0.14 B$    |
| 2025-05-09 | 0.03  | 0.12 B$    |
| 2024-11-07 | 0.03  | 0.08 B$    |
| 2025-11-05 | 0.03  | 0.08 B$    |

**Analysis:**

*   **EPS:** The EPS shows a significant jump in the most recent quarter (2025-11-05), indicating a substantial improvement in profitability.
*   **Revenue:** Revenue has been consistently growing over the past few quarters, suggesting strong sales performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.16B   | 82.63%        |
| 2025-06-30 | $0.14B   | 86.58%        |
| 2025-03-31 | $0.12B   | 87.14%        |
| 2024-12-31 | $0.11B   | 85.77%        |
| 2024-09-30 | $0.08B   | 88.86%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-09-30 | $0.61B   | 64.37%    |
| 2025-06-30 | $0.28B   | 10.20%    |
| 2025-03-31 | $0.24B   | 2.13%     |
| 2024-12-31 | $0.22B   | 10.49%    |
| 2024-09-30 | $0.19B   | 2.02%     |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows consistent growth, and profit margins are very high, indicating efficient operations and strong pricing power.
*   **Capital and Profitability:** Equity has increased significantly, particularly in the most recent quarter. The Return on Equity (ROE) shows a massive spike in the latest quarter, reflecting the strong profitability.

**7. Summary Analysis**

TGTX presents a complex investment picture:

*   **Positives:** Strong recent earnings and revenue growth, high profit margins, increasing equity, and a "Buy" consensus from analysts.
*   **Negatives:**  Historical underperformance relative to the S&P 500, volatile past performance (as reflected in the CAGR and Alpha data), negative long-term expected return, and concerning news related to competitor results and margin challenges. The significant jump in earnings in the most recent quarter needs further investigation to determine if it is sustainable.
*   **Technical Indicators:** The RSI is nearing oversold, which might suggest a buying opportunity, but the negative PPO signals caution. The Hybrid Signal is bearish.

**Overall Recommendation:**

Given the mixed signals, a cautious approach is warranted.  The recent earnings jump and analyst optimism are encouraging, but the negative news and historical performance issues cannot be ignored.  Further due diligence is needed to understand the sustainability of recent positive trends and the potential impact of the negative factors before making any investment decision. Investors should carefully weigh the risks and potential rewards before investing in TGTX.

